DOCSLIB.ORG

New Advances in Canine Allergic Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Advances in Canine Allergic Disease PROCEEDINGS OF A SYMPOSIUM HELD AT THE 8TH WORLD CONGRESS OF VETERINARY DERMATOLOGY I BORDEAUX, FRANCE 1ST JUNE 2016 NEW ADVANCES IN CANINE ALLERGIC DISEASE ZOETIS PRINCIPAL SPONSOR OF THE 8TH WCVD IN BORDEAUX FOR ANIMALS. FOR HEALTH. FOR YOU. THE NEXT HORIZON: TARGETED ANTIBODY THERAPY FOR CANINE ALLERGIC SKIN DISEASE Zoetis is pleased to share with you the latest advances on Canine Atopic Dermatitis and how targeted antibody therapy may help manage itch and inflammation in allergic dogs. CONTENTS About the speakers Targeting Antibody Therapy for Successful Outcomes Dr. THIERRY OLIVRY Antibody Therapy: What’s Next in Veterinary Dermatology Dr. ANDREA GONZALES Practical Application of Antibody Therapy Dr. DOUGLAS J. DeBOER You can download this PDF at www.excellenceindermatology.com, and, request a link to the video recording of today’s proceedings at www.zoetismabs.com. Proceedings of a Symposium held at the 8th World Congress of Veterinary Dermatology, Bordeaux, France, June 1st 2016. The opinions expressed in the articles in this publication are those of the authors and do not necessarily reflect the official label recommendations and points of view of the company or companies that manufacture and/or market any of the pharmaceutical agents referred to. La présentation des produits est conforme au droit du pays dans lequel est établi le responsable de la communication. Le classement des médicaments au regard de la prescription et de la délivrance, les indications des médicaments peuvent être différents selon les pays. Il vous incombe de vérifier les conditions d’utilisation et de prescription / délivrance vous concernant. About the speakers DR. THIERRY OLIVRY ANDREA J. GONZALES DR. DOUGLAS J. DEBOER, DrVet, PhD, DECVD, DACVD PhD DVM, DACVD NORTH CAROLINA STATE UNIVERSITY GLOBAL THERAPEUTICS RESEARCH GROUP, ZOETIS UNIVERSITY OF WISCONSIN-MADISON After graduating from veterinary school in Dr. Gonzales is a Director in the Global Dr. DeBoer joined the faculty of the School of Toulouse (France) in 1984, Dr. Olivry became a Therapeutics Research group at Zoetis. She Veterinary Medicine, University of Wisconsin- partner in a specialty practice in Paris. In 1991, he received her PhD from the University of North Madison, in 1986 and is presently a Professor Carolina at Chapel Hill in 1997 and then trained of Dermatology there. His responsibilities moved to the US for a residency in dermatology as a postdoctoral fellow in the Cancer Research, include teaching foundation principles of clinical and a PhD in comparative pathology at the Experimental Therapy group at Legacy Parke- dermatology to veterinary students. Dr. DeBoer’s University of California Davis. He is board-certified Davis. She has over 15 years of experience in the research and clinical interests center on the by both European and American Colleges of pharmaceutical industry as a lead biologist in areas immunology of recurrent and chronic skin diseases, Veterinary Dermatology. Dr. Olivry is Professor of such as Allergy and Dermatology, Inflammation, with a focus on canine allergic skin diseases Immunodermatology at the North Carolina State Oncology, and Drug Safety Evaluation in Animal and feline dermatophytosis. A diplomate of the University College of Veterinary Medicine. He Health as well as Human Health divisions of American College of Veterinary Dermatology, holds also an appointment as Adjunct Research Pfizer Inc. Current roles include understanding he received the ACVD Award of Excellence for Associate Professor of Dermatology at the mechanisms involved in the pathobioloy of canine Contributions to Science and Education in 2003. University of North Carolina-Chapel Hill School of atopic dermatitis (CAD) and identifying new Dr. DeBoer has served on the scientific editorial Medicine. From 2001 to 2004, he was the Chair targets for therapeutic intervention in allergic boards of the American Journal of Veterinary conditions in companion animals. She also Research and Veterinary Dermatology and is of the International Task Force on Canine Atopic manages a laboratory consisting of 12 colleagues chair of the International Committee on Allergic Dermatitis, and from 2008 to 2009, President of with expertise in investigative pharmacology, in Diseases of Animals. He is a graduate of the School the European College of Veterinary Dermatology. vitro assay design and biomarker identification of Veterinary Medicine at University of California, for animal health indications. Her group employs Davis, and completed postgraduate training at Dr. Olivry has been recognized with the “ACVD state-of-the-art technologies and high-throughput Michigan State University and at UC Davis. Award for Excellence for Outstanding Contri- screening approaches to aid in the identification butions to Science and Education” in 2004, the and efficient progression of experimental “NCSU Clinician of the Year award” in 2005, the therapeutics to registration. “Pfizer Award for Research Excellence at NCSU” in 2010 and the “ World Small Animal Veterinary As- sociation (WSAVA) Hill’s Excellence in Veterinary Healthcare Award” in 2013. Dr. Olivry has authored more than 210 peer-reviewed original articles, and he has lectured extensively all over the world to veterinary and medical audiences. His current areas of research interest are canine atopic dermatitis and the mechanism and treatment of itch in dogs. 4 NEW ADVANCES IN CANINE ALLERGIC DISEASE DR. THIERRY OLIVRY DrVet, PhD, DECVD, DACVD KEY POINTS > Species-specific recombinant monoclonal > In heterogeneous syndromes such as atopic Targeting antibodies (mAbs) belong to a new class of dermatitis and psoriasis, the pathogenesis of skin biotherapeutics. These biologics are capable of lesions varies depending upon their stage. Finding binding to a single antigenic epitope, and the the right target is difficult because of the myriad specificity of the antigen-antibody bond gives of cells and mediators involved in the inflammation Antibody them a unique target and mode of action. cascade. Recent research in the pathogenesis of these two complex inflammatory skin diseases has • Compared to small molecules, mAbs have helped identify early pro-inflammatory cytokines Therapy for several advantages: that are now the target of therapeutic mAbs. For atopic dermatitis, dupilumab targeting the IL-4/ • They are generally safe IL-13 receptor alpha appears to have a remarkable • They typically require infrequent dosing beneficial effect. For psoriasis, brodalumab (weekly to monthly) as a result of a long targeting the IL-17 receptor and tildrakizumab Successful serum half-life blocking the IL-23 p19 hold the highest potential for induction of lesion remission. > They can often be administered by subcutaneous Outcomes injections > Because of the unique specificity of the mAbs, knowledge of disease pathogenesis is key to > Therapeutic mAbs can target soluble molecules, identifying potential targets. Unfortunately, the such as cytokines, before they bind and activate more complex the disease pathomechanism, the their receptor, or they can block the cytokine less likely theory or experimental models may be receptor itself. These biologics can also bind to fully predictive of the clinical impact of targeting a membrane molecules on tumor cells to enhance single antigen. Ultimately, clinical trials will have to SUMMARY their destruction by immune cells or activated prove whether laboratory predictions can translate complement. Monoclonal antibodies are also being into clinical benefit for either human or animal developed as anti-infectious agents. patients. > Species-specific recombinant monoclonal antibodies (mAbs) are precision and stealthy > Monoclonal antibodies are exquisitely targeted “weapons” that are unique in their specific binding therapies; the benefit and safety profile of a given to their target; they are generally safe and have the mAb for treatment of prevention of a disease will advantage of infrequent dosing. depend mainly from the specificity of the targeted antigen. > Identifying the right target to be inhibited by > In some diseases, identifying the molecule to mAbs can be straightforward in case of simple be targeted by mAbs is straightforward due to disease pathogenesis. For complex inflammatory a relatively simple pathogenesis. Examples of skin diseases such as psoriasis and atopic such mAbs are rituximab that binds to CD20 dermatitis, the pathogenesis of skin lesions expressed by neoplastic B cells in some subsets involves many cells and mediators, which are often of non-Hodgkins lymphoma or omalizumab that redundant. Knowledge of disease pathogenesis is was designed to inhibit IgE in cases of refractory critical to the identification of the best target for asthma and chronic idiopathic urticaria. mAbs, but theory does not always translate into clinical benefit. 6 NEW ADVANCES IN CANINE ALLERGIC DISEASE NOTES NOTES SLIDE 1 SLIDE 5 SLIDE 2 SLIDE 6 SLIDE 3 SLIDE 7 SLIDE 4 SLIDE 8 8 NEW ADVANCES IN CANINE ALLERGIC DISEASE NOTES NOTES SLIDE 9 SLIDE 13 SLIDE 10 SLIDE 14 SLIDE 11 SLIDE 15 SLIDE 12 SLIDE 16 10 NEW ADVANCES IN CANINE ALLERGIC DISEASE NOTES NOTES SLIDE 17 SLIDE 21 SLIDE 18 SLIDE 22 SLIDE 19 SLIDE 23 SLIDE 20 SLIDE 24 12 NEW ADVANCES IN CANINE ALLERGIC DISEASE NOTES NOTES SLIDE 25 SLIDE 29 SLIDE 26 SLIDE 30 SLIDE 27 SLIDE 31 SLIDE 28 SLIDE 32 14 NEW ADVANCES IN CANINE ALLERGIC DISEASE NOTES NOTES SLIDE 33 SLIDE 34 16 NEW ADVANCES IN CANINE ALLERGIC DISEASE DR. ANDREA GONZALES PhD KEY POINTS • Rapid inhibition of pruritus by oclacitinib in flea
Load more

Recommended publications
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Atopic Dermatitis in Animals and People: an Update and Comparative Review
    veterinary sciences Review Atopic Dermatitis in Animals and People: An Update and Comparative Review Rosanna Marsella 1,2,* and Anna De Benedetto 1 1 Department of Dermatology, College of Medicine, University of Florida, 4037 NW 86 Terrace, Gainesville, FL 32606, USA; [email protected]fl.edu 2 Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, 2015 SW 16th Avenue, Gainesville, FL 32610, USA * Correspondence: Marsella@ufl.edu; Tel.: +1-352-278-0742 Academic Editor: Rob Siebers Received: 13 June 2017; Accepted: 22 July 2017; Published: 26 July 2017 Abstract: Atopic dermatitis is an extremely common, pruritic, and frustrating disease to treat in both people and animals. Atopic dermatitis is multifactorial and results from complex interactions between genetic and environmental factors. Much progress has been done in recent years in terms of understanding the complex pathogenesis of this clinical syndrome and the identification of new treatments. As we learn more about it, we appreciate the striking similarities that exist in the clinical manifestations of this disease across species. Both in animals and people, atopic disease is becoming increasingly common and important similarities exist in terms of immunologic aberrations and the propensity for allergic sensitization. The purpose of this review is to highlight the most recent views on atopic dermatitis in both domestic species and in people emphasizing the similarities and the differences. A comparative approach can be beneficial in understanding the natural course of this disease and the variable response to existing therapies. Keywords: atopic dermatitis; skin barrier; atopic march; dogs; cats; horses; humans 1. Introduction Increasing awareness exists with respect to the similarities between animal and human diseases and the appreciation of how a comparative approach is useful to improve our understanding of pathogenesis and the development of new treatments [1,2].
    [Show full text]
  • World Congress Veterinary Dermatology (WCVD) Summary by Dr Carmen Lorente, DVM, Phd, Dipecvd EBVS® European Specialist in Veterinary Dermatology
    Quality Veterinary Diagnostics BattLab from disease to optimal health Quality Veterinary Diagnostics from Disease to Optimal Health LABORATORY FOR CLINICAL DIAGNOSTICS Third World Congress Veterinary Dermatology (WCVD) Summary By Dr Carmen Lorente, DVM, PhD, DipECVD EBVS® European Specialist in Veterinary Dermatology Our third summary from the digital World Congress in Veterinary Dermatology 2020 (WCVD) focuses on two exciting therapies: biological therapy and bacteriophage therapy. They are old therapies but with a tremendous and developing future in managing complex diseases including resistant bacterial, atopic dermatitis, pruritus and cancer. Below are some summary points from the talk by Dr Douglas DeBoer on the subject of “Biological therapies in dermatology” and the lecture “Bacteriophage therapy for challenging bacterial infections” from Dr Richard Squires. Biological Therapy: What is biological therapy? Biological therapy is the use of a biological compound, not a chemical, to treat disease. It is designed to stimulate or restore the ability of the body’s immune (natural internal defence) system to fight infection and disease. It is also called biological response modifier therapy (BRM), biotherapy or immunotherapy. The therapeutic substances may occur naturally in the body or be made in laboratory cultures rather than chemical synthesis. BRMs are not metabolised like a drug, don’t pass through the liver or kidneys, have a long-lasting action in the body and are very targeted. Which kind of biological therapy and biological response modifiers (BRM) exist? Biological therapy or immunotherapy can be active (where the immune system has to react) or passive (administration of an immunologic molecule like an antibody (Ab) or something similar).
    [Show full text]
  • Clinical Efficacy of Oclacitinib and Lokivetmab in Dogs with Canine Atopic Dermatitis
    Original Article pISSN 1598-298X • eISSN 2384-0749 J Vet Clin 2021;38:127-134 https://doi.org/10.17555/jvc.2021.38.3.127 JVCJournal of Veterinary Clinics Clinical Efficacy of Oclacitinib and Lokivetmab in Dogs with Canine Atopic Dermatitis Sora Lee Abstract Canine atopic dermatitis (CAD) is a genetically predisposed inflamma- Taesik Yun tory and pruritic skin disease presenting characteristic clinical features in dogs. Yoonhoi Koo Despite oclacitinib and lokivetmab being commonly used, no study has compared Yeon Chae their efficacies in CAD. This study aimed to compare the efficacy, safety, and con- Dohee Lee trol of CAD-associated pruritus and skin lesions between oclacitinib and lokivet- Dongjoon Choi mab. It also investigated whether switching to lokivetmab from oclacitinib or pred- Yujin Choi nisolone had any benefits. Twenty-five client-owned dogs, newly diagnosed with Hakhyun Kim CAD, were allocated to the oclacitinib (n = 20) and lokivetmab (n = 5) groups and Mhan-Pyo Yang administered oclacitinib (0.4-0.6 mg/kg orally, twice daily for 14 days, then once Byeong-Teck Kang* daily) and lokivetmab (2 mg/kg subcutaneously, every month) for 8 weeks, respec- tively. The switching group included five dogs previously administered with oclac- Laboratory of Veterinary Internal Med- itinib (n = 4) or prednisolone (n = 1) who were switched to lokivetmab directly at icine, College of Veterinary Medicine, the start of the study. The pruritus visual analog scale (PVAS) and Canine Atopic Chungbuk National University, Cheongju 28644, Korea Dermatitis Extent and Severity Index (CADESI-04) values were surveyed at weeks 0, 4, and 8. Oclacitinib and lokivetmab significantly reduced the PVAS and CADE- SI-04 scores.
    [Show full text]
  • Farmaatsia- Terminoloogia Teine, Täiendatud Trükk
    Farmaatsia- terminoloogia Teine, täiendatud trükk Graanulid Suspensioon Lahus Emulsioon Pillid Pulber Salv Kreem Aerosool Plaaster Sprei Pastill Tampoon Oblaat Emulsioon Kontsentraat Silmageel Tablett Haavapulk Ninatilgad Kapsel Lakukivi Inhalaator Farmaatsia- terminoloogia Teine, täiendatud trükk Tartu 2019 Koostajad: Toivo Hinrikus, Karin Kogermann, Ott Laius, Signe Leito, Ain Raal, Andres Soosaar, Triin Teppor, Daisy Volmer Keeletoimetaja: Tiina Kuusk Kirjastanud: Ravimiamet Nooruse 1, 50411 Tartu Telefon: +372 737 4140 Faks: +372 737 4142 E-post: [email protected] Esimene trükk 2010 Teine, täiendatud trükk 2019 Raamat on leitav Ravimiameti veebilehelt: www.ravimiamet.ee/farmaatsiaterminoloogia Väljaande refereerimisel või tsiteerimisel palume viidata allikale. ISBN 978-9949-9697-3-9 Sisukord Farmaatsiaterminoloogia Eestis..........................................................................................5 Üldised farmaatsiaalased terminid ...................................................................................10 Euroopa farmakopöa ......................................................................................................... 21 Euroopa farmakopöa sõnastik ..........................................................................................24 Standardterminid ..............................................................................................................29 Ravimvormid .....................................................................................................................29
    [Show full text]
  • Therapeutic Complications and Follow-Up in a Dog with Atopic Dermatitis
    168 Case report Vlaams Diergeneeskundig Tijdschrift, 2019, 88 Therapeutic complications and follow-up in a dog with atopic dermatitis Therapeutische complicaties en opvolging bij een hond met atopische dermatitis C. Meere, S. Vandenabeele Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke [email protected] A BSTRACT In this case report, the therapeutic follow-up of a four-year-old, male, castrated Shih Tzu with atopic dermatitis is described. The treatment first consisted of prednisolone (Prednisolone®), followed by oclacitinib (Apoquel®) and afterwards lokivetmab (Cytopoint®). Furthermore, the diagnosis of AD and the different treatment options are discussed. In addition, more information is given about lokivetmab (Cytopoint®), a new therapeutic agent. SAMENVATTING In deze casereport wordt de therapeutische opvolging van een vier jaar oude, mannelijke, gecas- treerde shih tzu met atopische dermatitis (AD) beschreven. De hond werd behandeld met prednisolone (Prednisolone®), vervolgens met oclacitinib (Apoquel®) en daarna met lokivetmab (Cytopoint®). In de discussie worden de diagnostische aanpak en de verschillende types van behandeling kritisch be- sproken. Verder wordt ingegaan op de recente therapie met lokivetmab (Cytopoint®). INTRODUCTION Up to 10% of the dogs worldwide suffer from AD, and therefore, practical guidelines are important Canine atopic dermatitis (AD) has been recognized to diagnose the disease properly (Scott et al., 2001; for a long time. In 1941, the first detailed case report Lund et al., 2009). Certain breeds are more predis- of ‘spontaneous allergy’, i.e. atopy in a dog with con- posed to AD than others suggesting a genetically me- junctivitis, urticaria and rhiitis was published. An al- diated, familial condition (Nutall et al., 2013).
    [Show full text]
  • Lecture Overview
    CVMA-SBCV Chapter Fall Conference and Trade Show Apoquel vs. Cytopoint November 3rd 2019 Lecture overview ‣ Introduction ‣ Dosage, administration, presentation ‣ Indications ‣ Mechanism of action ‣ Pharmacology ‣ Efficacy, safety, contraindications, cautions ‣ Monitoring ‣ Selection CONFIDENTIAL INFORMATION - MARS INC. 1 Introduction ‣ The two “new kids on the block” for allergic dermatoses are oclacitinib (Apoquel™) and lokivetmab (Cytopoint®). ‣ These first-in-class medicines give veterinarians effective and safe additional options to customize atopic dermatitis treatment for canine patients. ‣ Though these treatments have similar indications, there are some substantial differences in their mechanism of action, administration, contraindications, safety profiles, and other details that require careful consideration when selecting them for different patients. CONFIDENTIAL INFORMATION - MARS INC. 2 Dr. Vincent Defalque Diplomate of the American College of Veterinary Dermatology North West Veterinary Dermatology Services CVMA-SBCV Chapter Fall Conference and Trade Show Apoquel vs. Cytopoint November 3rd 2019 New therapies for use in dogs in Canada 2016 2017 CONFIDENTIAL INFORMATION - MARS INC. 3 Dosage, Administration, and Presentation ‣ Apoquel™ is an orally-administered film-coated tablet containing oclacitinib maleate. ‣ It is available in 3 tablet strengths: 3.6 mg, 5.4 mg, and 16 mg. ‣ Marked with AQ and either S, M, or L on both sides. ‣ Non-flavoured tablets are scored in half for convenient dosing in dogs: At least 12 months of age Ranging from 3 to 80 kg ‣ Further division has not been evaluated. ‣ Packaged in bottles of 100 tablets. ‣ Administer orally at a dose of 0.4 to 0.6 mg/kg (according to the dosing table) q12h for up to 14 days followed by q24h for maintenance therapy.
    [Show full text]
  • Regulation of Skin Barrier Function Via Competition Between AHR Axis
    Journal of Clinical Medicine Review Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4-JAK-STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis Masutaka Furue 1,2 1 Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan; [email protected]; Tel.: +81-92-642-5581; Fax: +81-92-642-5600 2 Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka 812-8582, Japan Received: 4 November 2020; Accepted: 19 November 2020; Published: 20 November 2020 Abstract: Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction, and chronic pruritus. As the anti-interleukin-4 (IL-4) receptor α antibody dupilumab improves all three cardinal features of AD, the type 2 cytokines IL-4 and especially IL-13 have been indicated to have pathogenic significance in AD. Accumulating evidence has shown that the skin barrier function is regulated via competition between the aryl hydrocarbon receptor (AHR) axis (up-regulation of barrier) and the IL-13/IL-4-JAK-STAT6/STAT3 axis (down-regulation of barrier). This latter axis also induces oxidative stress, which exacerbates inflammation. Conventional and recently developed agents for treating AD such as steroid, calcineurin inhibitors, cyclosporine, dupilumab, and JAK inhibitors inhibit the IL-13/IL-4-JAK-STAT6/STAT3 axis, while older remedies such as coal tar and glyteer are antioxidative AHR agonists. In this article, I summarize the pathogenic and therapeutic implications of the IL-13/IL-4-JAK-STAT6/STAT3 axis and the AHR axis in AD.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
    US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]